These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 28095573

  • 1. Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris.
    Eichenfield LF, Gold LS, Nahm WK, Cook-Bolden FE, Pariser DM.
    J Drugs Dermatol; 2016 Dec 01; 15(12):1496-15027. PubMed ID: 28095573
    [Abstract] [Full Text] [Related]

  • 2. Results of a Phase 2 Efficacy and Safety Study with SB204, an Investigational Topical Nitric Oxide-releasing Drug for the Treatment of Acne Vulgaris.
    Baldwin H, Blanco D, McKeever C, Paz N, Vasquez YN, Quiring J, Enloe C, De León E, Stasko N.
    J Clin Aesthet Dermatol; 2016 Aug 01; 9(8):12-8. PubMed ID: 27672413
    [Abstract] [Full Text] [Related]

  • 3. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3 %/Benzoyl Peroxide 2.5 % Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study.
    Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E.
    Am J Clin Dermatol; 2016 Jun 01; 17(3):293-303. PubMed ID: 26945741
    [Abstract] [Full Text] [Related]

  • 4. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
    Kircik LH, Baldwin H, Lain E, Guenin E, Harris S, Bhatt V.
    J Drugs Dermatol; 2019 Feb 01; 18(2):178-188. PubMed ID: 30811141
    [Abstract] [Full Text] [Related]

  • 5. A Phase 2b, Randomized, Double-Blind Vehicle Controlled, Dose Escalation Study Evaluating Clascoterone 0.1%, 0.5%, and 1% Topical Cream in Subjects With Facial Acne.
    Mazzetti A, Moro L, Gerloni M, Cartwright M.
    J Drugs Dermatol; 2019 Jun 01; 18(6):570. PubMed ID: 31251550
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: First of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-controlled Trials.
    Stein Gold LF, Jarratt MT, Bucko AD, Grekin SK, Berlin JM, Bukhalo M, Weiss JS, Berk DR, Chang-Lin JE, Lin V, Kaoukhov A.
    J Drugs Dermatol; 2016 May 01; 15(5):553-61. PubMed ID: 27168264
    [Abstract] [Full Text] [Related]

  • 7. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides.
    Eichenfield LF, Draelos Z, Lucky AW, Hebert AA, Sugarman J, Stein Gold L, Rudisill D, Liu H, Manna V.
    J Drugs Dermatol; 2013 Jun 01; 12(6):611-8. PubMed ID: 23839175
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
    Eichenfield LF, Lain T, Frankel EH, Jones TM, Chang-Lin JE, Berk DR, Ruan S, Kaoukhov A.
    J Drugs Dermatol; 2016 Aug 01; 15(8):962-9. PubMed ID: 27537997
    [Abstract] [Full Text] [Related]

  • 9. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
    Cook-Bolden FE, Weinkle SH, Guenin E, Bhatt V.
    J Drugs Dermatol; 2019 Jan 01; 18(1):32-38. PubMed ID: 30681791
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC, Baldwin H, Stein Gold L, Guenin E.
    J Drugs Dermatol; 2019 Nov 01; 18(11):1147-1154. PubMed ID: 31741360
    [Abstract] [Full Text] [Related]

  • 11. Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study.
    Kawashima M, Hashimoto H, Alió Sáenz AB, Ono M, Yamada M.
    Br J Dermatol; 2015 Feb 01; 172(2):494-503. PubMed ID: 25040180
    [Abstract] [Full Text] [Related]

  • 12. Customized Single-agent Therapy Management of Severe Inflammatory Acne: A Randomized, Double-blind, Parallel-group, Controlled Study of a New Treatment--Adapalene 0.3%-Benzoyl Peroxide 2.5% Gel.
    Weiss J, Stein Gold L, Leoni M, Rueda MJ, Liu H, Tanghetti E.
    J Drugs Dermatol; 2015 Dec 01; 14(12):1427-35. PubMed ID: 26659936
    [Abstract] [Full Text] [Related]

  • 13. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
    Stein Gold L, Pariser DM, Guenin E.
    J Drugs Dermatol; 2019 Dec 01; 18(12):1218-1225. PubMed ID: 31860209
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study.
    Eichenfield LF, Alió Sáenz AB.
    J Drugs Dermatol; 2011 Dec 01; 10(12):1382-96. PubMed ID: 22134562
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE, Gold MH, Guenin E.
    J Drugs Dermatol; 2020 Jan 01; 19(1):78-85. PubMed ID: 32023013
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.